Top Story

Growth estimated in B-cell NHL treatment market value

August 30, 2014

The market value of B-cell non-Hodgkin’s lymphoma treatments will experience moderate growth across six major markets from $4.59 billion in 2013 to $5.41 billion by 2018, according to a report from GlobalData.

The research and consulting firm said that with the recent FDA approval of targeted B-cell receptor inhibitors ibrutinib (Imbruvica; Pharmacyclics, Janssen) and idelalisib (Zydelig, Gilead Sciences), the global NHL treatment paradigm will undergo a dramatic shift away from chemoimmunotherapy regimens.

In the Journals

S-1 noninferior to UFT/LV for stage III colon cancer

August 29, 2014
Adjuvant chemotherapy with the oral fluoropyrimidine derivative S-1 conferred similar DFS rates as tegafur-uracil plus leucovorin among patients with stage III

Survey shows doctors predominantly lead ACOs

August 29, 2014
Accountable Care Organizations are largely led by physicians or physician and hospital partnerships, according to data published in Health Affairs. “The broad…
In the Journals

Sunitinib active in meningioma

August 29, 2014
Sunitinib demonstrated encouraging activity in patients with recurrent and progressive meningioma, according to results of a prospective, multicenter, single-arm phase 2…
More News Headlines »
Cover Stories

Thyroid cancer treatment no longer ‘one-size-fits-all’ approach

HemOnc Today, July 10, 2014
Thyroid cancer incidence is increasing faster than any other malignancy in the United States.
More »
Meeting News Coverage Video
figure

Docetaxel plus ADT improved OS in metastatic prostate cancer

June 24, 2014
CHICAGO — Donald L. Trump, MD, FACP, president and CEO at Roswell Park Cancer Institute and HemOnc Today
More »